Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Docetaxel or Gemcitabine in Advanced Urothelial Cancer
NCT02437370Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Sep 2015
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in urothelial carcinoma (UC) (2 arms), sponsored by University of California, Davis. Primary endpoint: Maximum Tolerated Dose. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02437370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437370.